Valdelúcia Grinevicius

Dr. Valdelúcia Grinevicius

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Redox Biology
Verified
Journal Article
Open access
LCL.S.E.P.W. Castro
L.S.E.P.W. Castro
MKM.R. Kviecinski
M.R. Kviecinski
FOF. Ourique
F. Ourique
EPE.B. Parisotto
E.B. Parisotto
VGValdelúcia Grinevicius
Valdelúcia Grinevicius
RPRozângela Curi Pedrosa
Rozângela Curi Pedrosa
This work evaluated the antitumor effects of albendazole (ABZ) and its relationship with modulation of oxidative stress and induction of DNA damage. The present results showed that ABZ causes oxidative cleavage on calf-thymus DNA suggesting that this compound can break DNA. ABZ treatment decreased MCF-7 cell viability (EC50=44.9 for 24h) and inhibited MCF-7 colony formation (~67.5% at 5μM). Intracellular ROS levels increased with ABZ treatment (~123%). The antioxidant NAC is able to revert the cytotoxic effects, ROS generation and loss of mitochondrial membrane potential of MCF-7 cells treated with ABZ. Ehrlich carcinoma growth was inhibited (~32%) and survival time was elongated (~50%) in animals treated with ABZ. Oxidative biomarkers (TBARS and protein carbonyl levels) and activity of antioxidant enzymes (CAT, SOD and GR) increased, and reduced glutathione (GSH) was depleted in animals treated with ABZ, indicating an oxidative stress condition, leading to a DNA damage causing phosphorylation of histone H2A variant, H2AX, and triggering apoptosis signaling, which was confirmed by increasing Bax/Bcl-xL rate, p53 and Bax expression. We propose that ABZ induces oxidative stress promoting DNA fragmentation and triggering apoptosis and inducing cell death, making this drug a promising leader molecule for development of new antitumor drugs.

1 August 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
VGValdelúcia Grinevicius
Valdelúcia Grinevicius
MKMaicon Roberto Kviecinski
Maicon Roberto Kviecinski
NMNádia Sandrini Ramos Santos Mota
Nádia Sandrini Ramos Santos Mota
FOFabiana Ourique
Fabiana Ourique
LCLuiza Sheyla Evenni Porfirio Will Castro
Luiza Sheyla Evenni Porfirio Will Castro
RPRozângela Curi Pedrosa
Rozângela Curi Pedrosa

1 January 2018 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JHJosiane Hilbig
Josiane Hilbig
PPPriscila de Britto Policarpi
Priscila de Britto Policarpi
VGValdelúcia Grinevicius
Valdelúcia Grinevicius
NMNádia Sandrine Ramos Santos Mota
Nádia Sandrine Ramos Santos Mota
ITIsabela Maia Toaldo
Isabela Maia Toaldo
JBJane Mara Block
Jane Mara Block

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
DSDaniela C. dos Santos
Daniela C. dos Santos
Jamal RafiqueJamal Rafique
Jamal Rafique
Sumbal SabaSumbal Saba
Sumbal Saba
VGValdelúcia Grinevicius
Valdelúcia Grinevicius
DFDanilo W. Filho
Danilo W. Filho
FOFabiana Ourique
Fabiana Ourique
Glioblastoma multiforme (GBM) is a notably lethal brain tumor associated with high proliferation rate and therapeutic resistance, while currently effective treatment options are still lacking. Imidazo[1,2‐a]pyridine derivatives and organoselenium compounds are largely used in medicinal chemistry and drug development. This study is aimed at further investigating the antitumor mechanism of IP‐Se‐06 (3‐((2‐methoxyphenyl)selanyl)‐7‐methyl‐2‐phenylimidazol[1,2‐a]pyridine), a selenylated imidazo[1,2‐a]pyridine derivative in glioblastoma cells. IP‐Se‐06 exhibited high cytotoxicity against A172 cells (IC50 = 1.8 μM) and selectivity for this glioblastoma cell. The IP‐Se‐06 compound has pharmacological properties verified in its ADMET profile, especially related to blood‐brain barrier (BBB) permeability. At low concentration (1 μM), IP‐Se‐06 induced intracellular redox state modulation with depletion of TrxR and GSH levels as well as inhibition of NRF2 protein. IP‐Se‐06 also decreased mitochondrial membrane potential, induced cytochrome c release, and chromatin condensation. Furthermore, IP‐Se‐06 induced apoptosis by decreasing levels of Bcl‐xL while increasing levels of γ‐H2AX and p53 proteins. Treatment with IP‐Se‐06 induced cell cycle arrest and showed antiproliferative effect by inhibition of Akt/mTOR/HIF‐1α and ERK 1/2 signaling pathways. In addition, IP‐Se‐06 displayed significant inhibition of p38 MAPK and p‐p38, leading to inhibition of inflammasome complex proteins (NLRP3 and caspase‐1) in glioblastoma cells. These collective findings demonstrated that IP‐Se‐06 is a bioactive molecule that can be considered a candidate for the development of a novel drug for glioblastoma treatment.

1 January 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
FOFabiana Ourique
Fabiana Ourique
MKMaicon R. Kviecinski
Maicon R. Kviecinski
KFKarina Bettega Felipe
Karina Bettega Felipe
JCJoão Francisco Gomes Correia
João Francisco Gomes Correia
MFMirelle S. Farias
Mirelle S. Farias
RPRozângela Curi Pedrosa
Rozângela Curi Pedrosa
The aim of this study was to enhance the understanding of the antitumor mechanism of 1,4-naphthoquinones and ascorbate. Juglone, phenylaminonaphthoquinone-7, and 9 (Q7/Q9) were evaluated for effects on CT-DNA and DNA of cancer cells. Evaluations in MCF-7 cells are DNA damage, ROS levels, viability, and proliferation. Proteins from MCF-7 lysates were immunoblotted for verifying PARP integrity,γH2AX, and pAkt. Antitumor activity was measured in Ehrlich ascites carcinoma-bearing mice. The same markers of molecular toxicity were assessedin vivo. The naphthoquinones intercalate into CT-DNA and caused oxidative cleavage, which is increased in the presence of ascorbate. Treatments caused DNA damage and reduced viability and proliferation of MCF-7 cells. Effects were potentiated by ascorbate. No PARP cleavage was observed. Naphthoquinones, combined with ascorbate, caused phosphorylation of H2AX and inhibited pAkt. ROS were enhanced in MCF-7 cells, particularly by the juglone and Q7 plus ascorbate. Ehrlich carcinoma was inhibited by juglone, Q7, or Q9, but the potentiating effect of ascorbate was reproducedin vivoonly in the cases of juglone and Q7, which caused up to 60% inhibition of tumor and the largest extension of survival. Juglone and Q7 plus ascorbate caused enhanced ROS and DNA damage and inhibited pAkt also in Ehrlich carcinoma cells.

1 October 2019 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
VGValdelúcia Grinevicius
Valdelúcia Grinevicius
KAKátia S. Andrade
Kátia S. Andrade
NMNádia S.R.S. Mota
Nádia S.R.S. Mota
LBLizandra C. Bretanha
Lizandra C. Bretanha
KFKarina Bettega Felipe
Karina Bettega Felipe
RPRozângela Curi Pedrosa
Rozângela Curi Pedrosa